Shigeo Negi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shigeo Negi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Takashi Shigematsu
Department of Nephrology, Wakayama Medical University, Wakayama, Japan
11 shared publicationsDaisuke Koreeda
Department of Nephrology, Wakayama Medical University, Wakayama, Japan
4 shared publicationsKouichi Tatsuta
2 shared publicationsSou Kobayashi
Department of Nephrology, Wakayama Medical University, Wakayama, Japan
2 shared publicationsYoshiyuki Hanba
2 shared publicationsHikari Oda
1 shared publication
Latest Publications
- 8 May 2018
- Published by Wiley in Seminars in Dialysis
- Vol. 31 (5) , 519-527
Acute kidney injury: Epidemiology, outcomes, complications, and therapeutic strategies
Acute kidney injury (AKI) is one of the most common serious complications for all hospital admissions, with its incidence increasing among hospitalized patients, particularly those in the intensive care unit. Despite significant improvements in critical care and dialysis technology, AKI is associated with an increased risk of short‐ and long‐term mortality, prolonged hospital stays, and dialysis dependence. These risks are particularly relevant for critically ill patients with AKI severe enough to require renal replacement therapy (RRT). No specific pharmacologic treatment has been established to treat AKI. Hence, the mainstay treatment for patients with AKI is RRT even though there are still several problematic issues regarding its use including RRT modality, dose, and timing. Recently, the impact of AKI on an increased risk of progression to chronic kidney disease (CKD) and end‐stage renal disease requiring dialysis or transplantation is attracting increased attention.
- 8 May 2018
- Published by Wiley in Seminars in Dialysis
- Vol. 31 (5) , 519-527
Acute kidney injury: Epidemiology, outcomes, complications, and therapeutic strategies
Acute kidney injury (AKI) is one of the most common serious complications for all hospital admissions, with its incidence increasing among hospitalized patients, particularly those in the intensive care unit. Despite significant improvements in critical care and dialysis technology, AKI is associated with an increased risk of short‐ and long‐term mortality, prolonged hospital stays, and dialysis dependence. These risks are particularly relevant for critically ill patients with AKI severe enough to require renal replacement therapy (RRT). No specific pharmacologic treatment has been established to treat AKI. Hence, the mainstay treatment for patients with AKI is RRT even though there are still several problematic issues regarding its use including RRT modality, dose, and timing. Recently, the impact of AKI on an increased risk of progression to chronic kidney disease (CKD) and end‐stage renal disease requiring dialysis or transplantation is attracting increased attention.
- Open Access
- 27 June 2016
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 2 (1) , 31
Renal replacement therapy for acute kidney injury
- 27 June 2016
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 2 (1) , 31
Open AccessRenal replacement therapy for acute kidney injury
- 1 January 2015
- Vol. 57 (2) , 296-301
[Therapeutic consideration in the intensive care unit of patients with chronic kidney disease or end-stage renal disease].
- 1 January 2015
- Vol. 57 (2) , 296-301
[Therapeutic consideration in the intensive care unit of patients with chronic kidney disease or end-stage renal disease].
- 1 January 2013
- Vol. 55 (4) , 534-8
[Dialysis medicine and risk management in disaster].
- 1 October 2012
- Vol. 22 (10) , 1557-66
[Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
Hyperphosphatemia is the most common complication among patients with chronic kidney disease. Large scale observational studies have identified hyperphosphatemia as an independent risk factor for cardiovascular disease and mortality in hemodialysis patients. The combination therapy of dietary phosphate restriction and phosphate removal with dialysis treatment is still not enough to achieve the serum phosphate within the target. Thererfore, phosphate binders is necessary for many dialyzed patients with hyperphosphatemia. In this article, we will review the detail and development of phosphate binders and recommendation for clinical practice in hyperphosphatemia.
- 1 October 2012
- Vol. 22 (10) , 1557-66
[Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
Hyperphosphatemia is the most common complication among patients with chronic kidney disease. Large scale observational studies have identified hyperphosphatemia as an independent risk factor for cardiovascular disease and mortality in hemodialysis patients. The combination therapy of dietary phosphate restriction and phosphate removal with dialysis treatment is still not enough to achieve the serum phosphate within the target. Thererfore, phosphate binders is necessary for many dialyzed patients with hyperphosphatemia. In this article, we will review the detail and development of phosphate binders and recommendation for clinical practice in hyperphosphatemia.
- 29 August 2012
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 16 (5) , 672-678
Current therapeutic strategies for acute kidney injury
Acute kidney injury (AKI) is characterized by a rapid decrease in kidney function and increased serum creatinine. The term acute renal failure (ARF) has been applied to such clinical manifestations. Despite several advances in the treatment of ARF, such as pharmacologic treatment and renal replacement therapy (RRT), the mortality rate among patients with ARF has changed little over the past four decades. It is widely recognized that ARF is associated with significantly increased morbidity and mortality especially in critically ill patients with ARF requiring RRT. Therefore, in order to improve outcomes in ARF patients, a new concept of AKI has been proposed. Recently the paradigm shift from ARF to AKI has been received by the research and clinical communities. In this review we will discuss the therapeutic strategies for AKI and focus on its management with an emphasis on RRT.
- 29 August 2012
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 16 (5) , 672-678
Current therapeutic strategies for acute kidney injury
Acute kidney injury (AKI) is characterized by a rapid decrease in kidney function and increased serum creatinine. The term acute renal failure (ARF) has been applied to such clinical manifestations. Despite several advances in the treatment of ARF, such as pharmacologic treatment and renal replacement therapy (RRT), the mortality rate among patients with ARF has changed little over the past four decades. It is widely recognized that ARF is associated with significantly increased morbidity and mortality especially in critically ill patients with ARF requiring RRT. Therefore, in order to improve outcomes in ARF patients, a new concept of AKI has been proposed. Recently the paradigm shift from ARF to AKI has been received by the research and clinical communities. In this review we will discuss the therapeutic strategies for AKI and focus on its management with an emphasis on RRT.
- 1 January 2012
- Vol. 54 (5) , 603-9
[Molecular targeting therapy in rheumatoid arthritis].
- 1 July 2010
- Vol. 20 (7) , 1096-102
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Hyperphosphatemia is a serious complication which has been linked with an increased risk of cardiovascular mortality in patients with chronic kidney disease. Lanthanum carbonate is a novel non-calcium, non-aluminum phosphate-binding agent, and has approved for clinical use in patients on hemodialysis in Japan on March in 2009. Compared to calcium carbonate and sevelamer hydrochloride, lanthanum carbonate is a powerful phosphate binder. There is no evidence of bone toxicity and neurotoxicity of lanthanum carbonate previously reported for aluminium hydroxide. However, further studies are needed to address the longer term toxic effect on bone and other organs.
- 1 July 2010
- Vol. 20 (7) , 1096-102
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Hyperphosphatemia is a serious complication which has been linked with an increased risk of cardiovascular mortality in patients with chronic kidney disease. Lanthanum carbonate is a novel non-calcium, non-aluminum phosphate-binding agent, and has approved for clinical use in patients on hemodialysis in Japan on March in 2009. Compared to calcium carbonate and sevelamer hydrochloride, lanthanum carbonate is a powerful phosphate binder. There is no evidence of bone toxicity and neurotoxicity of lanthanum carbonate previously reported for aluminium hydroxide. However, further studies are needed to address the longer term toxic effect on bone and other organs.
- 1 January 2009
- Vol. 51 (1) , 27-32
[Advances in blood purification medicine in 2008].